Therapiestrategien beim synchron metastasierten Kolonkarzinom

’t Lam-Boer J, Mol L, Verhoef C et al (2014) The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 14:741 ’t Lam-Boer J, Van Der Geest LG, Verhoef C et al (2016) Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the Netherlands. Int J Cancer 139:2082–2094 Anwar S, Peter MB, Dent J et al (2012) Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Colorectal Dis 14:920–930 Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713–1729 Biondo S, Frago R, Kreisler E et al (2017) Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis 32:1085–1090 Birgin E, Rasbach E, Seyfried S et al (2020) Contralateral liver hypertrophy and oncological outcome following radioembolization with (90)Y-microspheres: a systematic review. Cancers 12:294 Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671 Chan TW, Brown C, Ho CC et al (2010) Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol 33:52–55 Chang GJ (2021) Primary tumor resection in colorectal cancer with synchronous unresectable metastasis: time to end the debate? J Clin Oncol 39:1095–1097 Cook AD, Single R, Mccahill LE (2005) Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 12:637–645 De Mestier L, Manceau G, Neuzillet C et al (2014) Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol 6:156–169 Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739 Eisenberger A, Whelan RL, Neugut AI (2008) Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 23:559–568 Faron M, Pignon JP, Malka D et al (2015) Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 51:166–176 Figueras J, Torras J, Valls C et al (2007) Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 50:478–488 Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47 Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 (discussion 318–321) Golfinopoulos V, Salanti G, Pavlidis N et al (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898–911 Hasselgren K, Rosok BI, Larsen PN et al (2021) ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO. Ann Surg 273:442–448 Hegewisch-Becker S, Graeven U, Lerchenmüller CA et al (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16:1355–1369 Heinemann V, Von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075 Hofheinz RD, Stintzing S (2020) Personalized systemic treatment of metastatic colorectal cancer. Internist 61:699–710 Imanishi M, Yamamoto Y, Hamano Y et al (2019) Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer 106:69–77 Juo YY, Hyder O, Haider AH et al (2014) Is minimally invasive colon resection better than traditional approaches?: First comprehensive national examination with propensity score matching. JAMA Surg 149:177–184 Kanemitsu Y, Shitara K, Mizusawa J et al (2021) Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 39:1098–1107 Karoui M, Koubaa W, Delbaldo C et al (2008) Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 15:3440–3446 Kelly ME, Spolverato G, Le GN et al (2015) Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol 111:341–351 Kim DH, Kim B, Choi JH et al (2016) Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy. Int J Colorectal Dis 31:1767–1774 Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632–1643 Kuipers EJ, Grady WM, Lieberman D et al (2015) Colorectal cancer. Nat Rev Dis Primers 1:15065 Le DT, Kim TW, Van Cutsem E et al (2020) Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 38:11–19 Leebmann H, Piso P (2019) Hyperthermic intraperitoneal chemotherapy. Chirurg 90:593–604 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019) S3-Leitlinie Kolorektales Karzinom, Langversion 2.1. http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/. Zugegriffen: 7. Jan. 2022 Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609–1618 Lurvink RJ, Rovers KP, Nienhuijs SW et al (2021) Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases—a systematic review. J Gastrointest Oncol 12:S242–S258 Matsumoto T, Hasegawa S, Matsumoto S et al (2014) Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor. Dis Colon Rectum 57:679–686 Mccahill LE, Yothers G, Sharif S et al (2012) Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C‑10. J Clin Oncol 30:3223–3228 Meric-Bernstam F, Hurwitz H, Raghav KPS et al (2019) Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20:518–530 Modest DP, Denecke T, Pratschke J et al (2018) Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE‑3. Eur J Cancer 88:77–86 Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215 Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985–992 Park EJ, Baek JH, Choi GS et al (2020) The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial. Cancers 12:2306 Primrose J, Falk S, Finch-Jones M et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611 Quénet F, Elias D, Roca L et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:256–266 Rahbari NN, Birgin E, Bork U et al (2021) Anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis: a randomized clinical trial. JAMA Surg 156:31–40 Rahbari NN, Lordick F, Fink C et al (2012) Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS—a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer 12:142 Rahbari NN, Reissfelder C, Schulze-Bergkamen H et al (2014) Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer 14:174 Reissfelder C, Rahbari NN, Koch M et al (2009) Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 16:3279–3288 Riihimaki M, Hemminki A, Sundquist J et al (2016) Patterns of metastasis in colon and rectal cancer. Sci Rep 6:29765 Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196:722–728 Sarela AI, Guthrie JA, Seymour MT et al (2001) Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 88:1352–1356 Scheer MG, Sloots CE, Van Der Wilt GJ et al (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829–1835 Seyfried S, Herrle F, Schröter M et al (2021) Initial experiences with the implementation of the enhanced recovery after surgery (ERAS®) protocol. Chirurg 92:428–433 Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. Ca Cancer J Clin 65:5–29 Stintzing S, Miller-Phillips L, Modest DP et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE‑3 (AIO KRK-0306) study. Eur J Cancer 79:50–60 Tanis PJ, Pereira PNR, Van Hooft JE et al (2015) Resection of obstructive left-sided colon cancer at a national level: a prospective analysis of short-term outcomes in 1,816 patients. Dig Surg 32:317–324 Tebbutt NC, Norman AR, Cunningham D et al (2003) Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52:568–573 Temple LK, Hsieh L, Wong WD et al (2004) Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475–3484 Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572 Urvay S, Eren T, Civelek B et al (2020) The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases. J BUON 25:939–944 Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417 Van Rooijen KL, Shi Q, Goey KKH et al (2018) Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer 91:99–106 Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392–2401 Yang C, Rahbari NN, Mees ST et al (2015) Staged resection of bilobar colorectal liver metastases: surgical strategies. Langenbecks Arch Surg 400:633–640